Zumaeta AM, Wright A, Syngelaki A, et al. - As the treatment of the high‐risk group for preeclampsia (PE) with aspirin decreases the rate of early PE with delivery at < 34 weeks' gestation by about 80% and that of preterm PE with delivery at < 37 weeks by 60%, the first‐trimester screening for PE is crucial. Researchers here examined the value of adding placental growth factor (PlGF) and pregnancy‐associated plasma protein‐A (PAPP‐A) in first‐trimester screening for preterm PE by maternal factors, mean arterial pressure (MAP) and uterine artery pulsatility index (UtA‐PI). In addition, they inscribed the risk cut‐off and screen‐positive rate to attain a desired detection rate of PE if PAPP‐A rather than PlGF was to be employed for first‐trimester screening. For this non‐intervention screening study, they obtained data from prospective screening for adverse obstetric outcomes in women with singleton pregnancy attending for a routine first‐trimester hospital visit. They assessed data of 60,875 singleton pregnancies, including 1,736 (2.9%) that developed PE. Findings suggest that in first‐trimester screening for preeclampsia (PE), the racial composition of the study population, along with whether the biomarkers used for screening are MAP, UtA‐PI and PlGF or MAP, UtA‐PI and pregnancy‐associated plasma protein‐A (PAPP‐A), influenced the risk cut‐off and screen‐positive rate to attain a desired detection rate of PE. They suggest PlGF rather than PAPP‐A as the preferred biochemical marker in first‐trimester screening for PE. However, the same detection rate can be achieved but at a higher screen‐positive rate when using PAPP‐A rather than PlGF.